Golden Drugs Private Limited

Golden Drugs Private Limited - pharma in Bangalore, Karnataka, India. Directors, charges & compliance details.
CIN U24232KA2012PTC157474 Incorporated 27 August 2012 ROC Bangalore HQ Bangalore, Karnataka, India
Merged Private Limited Company pharma
Revenue · FY 2024
₹5.8 Cr
▼ 22% YoY
Net loss · FY 2024
₹2.55 Cr
Net margin -43.9%
EBITDA · FY 2024
-₹11.88 Lakh
EBITDA margin -2%
Authorised capital
₹4.5 Cr
Registered with MCA
Paid-up capital
₹3.59 Cr
Issued & subscribed
Open charges
₹20 Cr
Satisfied ₹24.5 Cr
Company age
14 yrs
Est. 2012
Employees · EPFO
80
Provident fund records

About Golden Drugs Private Limited

Data last updated:

Golden Drugs Private Limited was a private limited company based in Bangalore, Karnataka, India, operated as a subsidiary of Bal Pharma Limited. The company has been amalgamated - it was merged with another entity and no longer exists as a separate legal entity. It operated in the API manufacturers segment of the pharmaceuticals sector. It was incorporated on 27 August 2012.

The company was registered with the Registrar of Companies (ROC), Bangalore, under CIN U24232KA2012PTC157474. Its GSTIN is 29AAECG9048B1ZK (Karnataka). The company held 2 GST registrations, all of them active.

The company had an authorised share capital of ₹4.5 Cr and a paid-up capital of ₹3.59 Cr. It was formerly known as Golden Drug Private Limited. It was led by directors Ravindrakumar Kothari and Shailesh Dheerajmal Siroya.

Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office was at 10/1 Laxmi Narayan Complex 5th Floor Palace Road, Bangalore, Karnataka, India – 560052.

As per the financials filed for FY 2024, the company reported a revenue of ₹5.8 Cr, a decline of 22% compared to the previous year. For the same year it recorded a net loss of ₹2.55 Cr (net margin -43.9%) and EBITDA of -₹11.88 Lakh (EBITDA margin -2%). Revenue has grown at a compounded annual rate (CAGR) of 87% over three years.

The company had about 80 employees on its provident fund (EPFO) records before it was dissolved.

As per MCA filings, the company had open charges of ₹20 Cr and satisfied charges of ₹24.5 Cr on record. Court records list 4 cases involving the company, including 2 filed by the company and 2 filed against it. The company has 3 deals on record (2 funding rounds, 1 acquisition), with disclosed funding of ₹3.58 Cr; the latest was in March 2018. Its 5 peer companies in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 1 smaller; the largest is Deep Finechem Private Limited with revenue of ₹6.17 Cr.

The last known website on record is balpharma.com.

Company details

CIN U24232KA2012PTC157474
Registration Number 157474
Incorporation Date 27 August 2012
ROC Bangalore
Listing Status Unlisted
Company Status Amalgamated
Parent Company Bal Pharma Limited
Compliance Status Active Compliant

CIN history

Golden Drugs has one previous CIN (Corporate Identification Number): U24232RJ2012PTC039907. The current CIN is U24232KA2012PTC157474, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24232KA2012PTC157474Current
U24232RJ2012PTC039907Previous

Contact details

Golden Drugs Private Limited's registered office is in Bangalore, Karnataka. Its website is balpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    10/1 Laxmi Narayan Complex 5th Floor Palace Road, Bangalore, Karnataka, India – 560052
  • Industry
    Pharma, API Manufacturers

To see the full contact details of Golden Drugs Private Limited, buy the company report.

Comprehensive company report
Golden Drugs Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Business activity

The main business activity of Golden Drugs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Golden Drugs Private Limited, buy the company report.

Financials of Golden Drugs Private Limited

FY 2024 filings available

Golden Drugs Private Limited reported revenue of ₹5.8 Cr (down 22% YoY) for FY 2024.

Revenue · FY 2024
₹5.8 Cr ▼ 22%
Net loss · FY 2024
₹2.55 Cr margin -43.9%
EBITDA · FY 2024
-₹11.88 Lakh margin -2%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 22%
3 years · compounded
▲ 87%
EBITDA CAGR growth
1 year
▲ 54%
3 years · compounded
▲ 56%

Revenue fell 22% in the latest year, but over three years it has grown at a compounded annual rate (CAGR) of 87%. EBITDA rose 54% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹5.8 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA-₹11.88 Lakh
Profit Before Tax
Tax Expense
Net Profit (PAT)-₹2.55 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Profitability
EBITDA Margin-2%
Net Profit Margin-43.9%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Golden Drugs Private Limited, buy the company report.

Board of directors of Golden Drugs Private Limited

Golden Drugs has 2 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.

Directors (as last reported)
NameDesignationAppointment DateTenureStatus
Ravindrakumar KothariDirector15 Nov 20188 Years 0 MonthsAs last reported
Shailesh Dheerajmal SiroyaDirector12 Apr 20188 Years 7 MonthsAs last reported

Peer comparison

Golden Drugs Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (API Manufacturers), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Deep Finechem Private Limited₹6.17 Cr (FY 2024)-38.0%Dhule, Maharashtra, India
SM Labs Private Limited₹6.16 Cr (FY 2024)-23.0%Hyderabad, Telangana, India
B. Sharda Pharma-Chem Limited₹5.93 Cr (FY 2024)-10.0%Gujarat, India
Rati Pushp Intermediates Private Limited₹5.92 Cr (FY 2025)-20.0%Muzaffar Nagar, Uttar Pradesh, India
Golden Drugs Private Limitedthis company₹5.8 Cr (FY 2024)-₹2.55 Cr-43.9%-22.0%Bangalore, Karnataka, India
R A C S Pharmachem (India) Private Limited₹5.77 Cr (FY 2025)-51.0%Chikkaballapur Distri, Karnataka, India

To see the full peer comparison of Golden Drugs Private Limited, buy the company report.

Auditor

Golden Drugs Private Limited is audited by K N & Associates for the financial year 2024.

Auditor firmFinancial yearFirm registration number
K N & AssociatesFY 2024013495C

Shareholding

The shareholding of Golden Drugs Private Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2024FY 2023FY 2022FY 2021FY 2020
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Golden Drugs Private Limited, buy the company report.

Charges & borrowings

Open charges
₹20 Cr
Satisfied charges
₹24.5 Cr
Breakdown by lending institutions
Tata Capital Financial Services Limited₹15.00 Cr
Punjab National Bank₹9.50 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
28 Sep 2018100207862Tata Capital Financial Services Limited₹15 CrSatisfied
15 Oct 201410528894Punjab National Bank₹4 CrSatisfied
15 Oct 201410528892Punjab National Bank₹5.5 CrSatisfied

To see the full charge records of Golden Drugs Private Limited, buy the company report.

Total charge records: 3 View all charges

Deals & funding

Golden Drugs Private Limited has 3 deals on record (2 funding rounds, 1 acquisition), with disclosed funding of ₹3.58 Cr; the latest was in March 2018.

Total deals
3
Funding rounds
2
Acquisition
1
Disclosed funding
₹3.58 Cr

Deals on record (3 of 3)

WhenDealAmountParties
Mar 2018Acquisition₹7.42 CrBuyer: Bal Pharma Limited
Seller: Chander Khamesara HUF, 3 individuals
Mar 2016Funding round₹1.47 CrInvestors: Mayura Jewels (India) Private Limited , 3 individuals
Mar 2014Funding round₹2.12 CrInvestors: Chander Khamesara HUF, 3 individuals

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Golden Drugs Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

GST

Golden Drugs has 2 GST registrations: 2 active.

Total GSTINs
2
Active
2
GSTINStateStatusRegistered on
29AAECG9048B1ZKKarnatakaActive07 Sep 2019
08AAECG9048B1ZORajasthanActive01 Jul 2017

To see the full GST registrations and return filing status of Golden Drugs Private Limited, buy the company report.

Recent activity

Golden Drugs Private Limited has 9 board changes on record since 2016: 2 appointments and 7 cessations. The latest: Ravindrakumar Kothari ceased to be Additional Director on 30 Sep 2019.

AGM
Golden Drugs Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Filing
Golden Drugs Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Bangalore.
Charges
A charge registered on 28 Sep 2018 via Charge ID 100207862 with Tata Capital Financial Services Limited was fully satisfied on 24 Jan 2024.
Ceased
Ravindrakumar Kothari ceased to be Additional Director.
Ceased
Chander Khamesra ceased to be Director.
Ceased
Ramesh Daglia ceased to be Director.
Appointed
Ravindrakumar Kothari was appointed as Director.
Charges
A charge with Tata Capital Financial Services Limited of Rs. 15.00 Cr registered on 28 Sep 2018 with Charge ID 100207862 was modified on 17 Oct 2018.
Charges
A charge with Tata Capital Financial Services Limited amounted to Rs. 15.00 Cr with Charge ID 100207862 was registered on 28 Sep 2018.
Ceased
Shailesh Dheerajmal Siroya ceased to be Additional Director.
Appointed
Shailesh Dheerajmal Siroya was appointed as Director.
Ceased
Snehlata Dalal ceased to be Director.

7 earlier events are in the company report.

Frequently asked questions

Golden Drugs has been "Amalgamated" (merged) as per MCA records. The company was combined with another entity and no longer exists as a separate legal entity. Business activities, if any, continue under the successor entity.

Golden Drugs was a private limited company based in Bangalore, Karnataka, India. The company worked in api manufacturers, within the pharma industry. It was incorporated on 27 August 2012 and is registered under CIN U24232KA2012PTC157474. The company is recorded as amalgamated in MCA records and no longer exists as a legal entity.

Golden Drugs was incorporated on 27 August 2012. It is registered with the Registrar of Companies, Bangalore.

Golden Drugs had 2 directors:

The CIN (Corporate Identification Number) of Golden Drugs is U24232KA2012PTC157474. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

The registered office of Golden Drugs is at 101 Laxmi Narayan Complex 5th Floor Palace Road, Bangalore, Karnataka, India – 560052.

Golden Drugs can be reached through the website balpharma.com. Its registered office is in Bangalore, Karnataka, India.

The latest financial statements of Golden Drugs on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.

The GSTIN of Golden Drugs is 29AAECG9048B1ZK, registered in Karnataka. The company has 2 GST registrations in all, of which 2 are active. Other active GSTINs include 08AAECG9048B1ZO (Rajasthan).

Golden Drugs operated in the pharma industry, in the api manufacturers segment.

Golden Drugs has 3 deals on record (2 funding rounds, 1 acquisition), with disclosed funding of ₹3.58 Cr; the latest was in March 2018.